

Psychopharmacology in geriatric psychiatry: Optimizing medication use in older adults.

Alice Johnson*

Department of Psychiatry, Jewish General Hospital, McGill University, Montreal, QC, Canada

Introduction

The field of geriatric psychiatry has made significant advancements in recent years, with a growing understanding of the unique mental health challenges faced by older adults. Psychopharmacology, the study of how medications affect mental processes, plays a crucial role in the treatment of psychiatric disorders in this population [1]. However, optimizing medication use in older adults requires careful consideration due to physiological changes, coexisting medical conditions, and potential drug interactions. This article explores the importance of psychopharmacology in geriatric psychiatry and highlights strategies for optimizing medication use in older adults.

Age-related physiological changes

As individuals age, various physiological changes occur in the body, impacting the way medications are processed. These changes include alterations in liver and kidney function, reduced metabolic rate, changes in body composition, and decreased blood flow to vital organs. These age-related changes can significantly affect drug absorption, distribution, metabolism, and excretion. Therefore, it is crucial to consider these factors when prescribing and adjusting medications in older adults to avoid adverse effects or suboptimal therapeutic outcomes.

Polypharmacy and drug interactions

Polypharmacy, the use of multiple medications concurrently, is common among older adults who often have multiple chronic medical conditions. While polypharmacy can be necessary, it also increases the risk of drug interactions, side effects, and medication non-adherence. Older adults may also experience age-related changes in drug metabolism and elimination, further complicating the issue. It is essential for healthcare providers to be aware of potential drug-drug interactions and carefully assess the risks and benefits of each medication prescribed [2]. Regular medication reviews, deprescribing unnecessary medications, and utilizing alternative treatment options such as non-pharmacological interventions can help optimize medication use in this population.

Sensitivity to medication side effects

Older adults are often more sensitive to the side effects of medications compared to younger individuals. Adverse drug

reactions, including cognitive impairment, sedation, falls, and extrapyramidal symptoms, can be particularly concerning in older adults and contribute to functional decline and increased healthcare utilization. Therefore, it is crucial to use lower initial doses of medications and monitor for side effects closely. Adjustments to medication regimens may be necessary based on individual responses and tolerability [3].

Individualized treatment approach

Geriatric psychiatry recognizes the importance of individualized treatment plans for older adults, considering the unique characteristics and needs of each patient [4]. When prescribing psychotropic medications, healthcare providers should consider the patient's overall health, medical comorbidities, cognitive status, potential drug interactions, and the specific psychiatric condition being treated. Collaborative decision-making involving the patient, their caregivers, and a multidisciplinary healthcare team is essential to optimize treatment outcomes and minimize risks.

Non-pharmacological interventions

While psychopharmacology plays a vital role in geriatric psychiatry, non-pharmacological interventions should also be considered as first-line or adjunctive treatments. Psychotherapy, cognitive-behavioral therapy, and psychosocial interventions have demonstrated effectiveness in managing psychiatric conditions in older adults. These approaches can reduce the reliance on medications, minimize side effects, and promote overall well-being. Combining pharmacological and non-pharmacological interventions can lead to more comprehensive and personalized care for older adults [5].

Conclusion

Psychopharmacology is an essential component of geriatric psychiatry, enabling healthcare providers to address psychiatric disorders in older adults effectively. However, optimizing medication use in this population requires a nuanced approach that takes into account age-related physiological changes, polypharmacy, sensitivity to side effects, and individualized treatment considerations. By considering these factors, healthcare providers can work towards maximizing the benefits of psychopharmacology while minimizing risks, ultimately improving the mental health and well-being of older adults.

*Correspondence to: Alice Johnson, Department of Psychiatry, Jewish General Hospital, McGill University, Montreal, QC, Canada, Email: johnson.a@mail.mcgill.ca

Received: 01-Apr-2023, Manuscript No. AAAGP-23-98277; Editor assigned: 04-Apr-2023, PreQC No. AAAGP-23-98277 (PQ); Reviewed: 18-Apr-2023, QC No. AAAGP-23-98277;

Revised: 21-Apr-2023, Manuscript No. AAAGP-23-98277 (R); Published: 26-Apr-2023, DOI: 10.35841/aaagp-7.3.142

References

1. Rush AJ, Wisniewski SR, Warden D, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. *Arch Gen Psychiatry*. 2008;65(8):870-80.
2. Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. *J Clin Psychiatry*. 2017;78(6):14242.
3. Hull LE, Lynch KG, Oslin DW. VA primary care and mental health providers' comfort with genetic testing: survey results from the PRIME care study. *J Gen Intern Med*. 2019;34:799-801.
4. Lowe B, Decker O, Müller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. *Med Care*. 2008;266-74.
5. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD checklist for diagnostic and statistical manual of mental disorders—fifth edition (PCL-5) in veterans. *Psychol Assess*. 2016;28(11):1379.